Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis

Jahr

2023

Autoren

Sotirchos ES, Hu C, Smith MD, Lord HN, DuVal AL, Arrambide G, Montalban X, Akgün K, Ziemssen T, Naismith RT, Hersh CM, Hyland M, Krupp LB, Nicholas JA, Bermel RA, Mowry EM, Calabresi PA, Fitzgerald KC.

Verlag

Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.

Link

https://doi.org/10.1212/wnl.0000000000207957

Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis

A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

Funktionelle Elektrostimulation zur Versorgung bei paretischen Gangstörungen: Fokus auf Fußheberschwäche bei Multipler Sklerose

Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice